Atualização sobre osteossarcoma convencional

Luiz Eduardo Moreira Teixeira; Alex Guedes; Suely Akiko Nakagawa; Karine Corrêa Fonseca; Eduardo Ribeiro Lima

doi:10.1055/s-0043-1771483

Revista Brasileira de Ortopedia, Table of Contents

CC BY 4.0 · Rev Bras Ortop (Sao Paulo) 2024; 59(06): e815-e820
DOI: 10.1055/s-0043-1771483

Artigo de Atualização

Oncologia

Atualização sobre osteossarcoma convencional

Article in several languages: português | English

Luiz Eduardo Moreira Teixeira

¹Departamento do Aparelho Locomotor, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil

,

Alex Guedes

²Grupo de Oncologia Ortopédica, Hospital Santa Izabel, Santa Casa de Misericórdia da Bahia, Salvador, BA, Brasil

,

Suely Akiko Nakagawa

³Centro de Sarcomas e Tumores Ósseos, AC Camargo Cancer Center, São Paulo, SP, Brasil

,

Karine Corrêa Fonseca

⁴Grupo de Oncologia Pediátrico, Hospital das Clínicas, Belo Horizonte, MG, Brasil

,

Eduardo Ribeiro Lima

⁴Grupo de Oncologia Pediátrico, Hospital das Clínicas, Belo Horizonte, MG, Brasil

› Author Affiliations

Abstract

Resumo

O osteossarcoma convencional é um tumor de alto grau de malignidade caracterizado pela produção de matriz osteóide pelos osteoblastos malignos. Tipicamente acomete ossos longos de crianças e adolescentes e o tratamento inclui abordagem sistêmica com quimioterapia e abordagem cirúrgica local com ressecção ampla. Avanços recentes nos conceitos oncológicos, de imagem, planejamento cirúrgico e protocolos de tratamento oncológico permitem uma melhora na sobrevida e maior taxa de preservação de membros. Este artigo aborda o estado atual relativo a incidência, patologia, tratamento e prognóstico do osteossarcoma convencional de alto grau.

Palavras-chave

neoplasias - osteossarcoma - sarcomas

Full Text

References

Referências
1 Flanagan AM, Blay JY, Bovée JVMG. et al. Bone tumours: Introduction. In: WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours. 5th ed. Lyon, France: International Agency for Research on Cancer; 2020: 340-444
2 Baumhoer D, Böhling TO, Cates JMM. et al. Osteosarcoma. In: WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours. 5th ed. Lyon, France: International Agency for Research on Cancer; 2020: 403-409
3 Cole S, Gianferante DM, Zhu B, Mirabello L. Osteosarcoma: A Surveillance, Epidemiology, and End Results program-based analysis from 1975 to 2017. Cancer 2022; 128 (11) 2107-2118
4 Mansur SF, Barbosa CSP, Miranda D. et al. Sarcoma osteogênico - Estudo retrospectivo epidemiológico de 184 casos diagnosticados em Belo Horizonte, Minas Gerais. Rev Bras Ortop 1996; 31 (12) 995-1000
5 Castro HC, Ribeiro KCB, Bruniera P. Osteossarcoma: Experiência do Serviço de Oncologia Pediátrica da Santa Casa de Misericórdia de São Paulo. Rev Bras Ortop 2008; 43 (04) 108-115
6 Jadão FRS, Lima LS, Lopes JAS, Ribeiro MB. Avaliação dos fatores prognósticos e sobrevida de pacientes com Osteossarcoma atendidos em um Hospital Filantrópico de Teresina (PI), Brasil. Rev Bras Ortop 2013; 48 (01) 87-91
7 Presti PF, Macedo CRD, Caran EM, Rodrigues AHD, Petrilli AS. Estudo epidemiológico de câncer na adolescência em centro de referência. Rev Paul Pediatr 2012; 30 (02) 210-216
8 Yoshida A, Bredella MA, Gambarotti M, Sumathi VP. Low-grade central osteosarcoma. In: WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours, 5th ed. Lyon, France: International Agency for Research on Cancer; 2020: 400-402
9 Guedes A, Oliveira MBDR, Costa FM, de Melo AS. Updating on bone and soft tissue sarcomas staging. Rev Bras Ortop 2021; 56 (04) 411-418
10 Guedes A, Oliveira MBR, Melo AS, Carmo CCM. Update in imaging evaluation of bone and soft tissue sarcomas. [Published online: 2021-11-11] Rev Bras Ortop. Available from: https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0041-1736569
11 Wang J, Nord KH, O'Donnel PG, Yoshida A. Parosteal osteosarcoma. In: WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours, 5th ed. Lyon, France: International Agency for Research on Cancer; 2020: 410-413
12 Binitie O, Morris CD. Conventional Osteoblastic Osteosarcoma. In Orthopaedic Knowledge Update Musculoskeletal Tumors 4. Rosemont: Illinois: American Academy of Orthoopaedic Surgeons; 2021: 169-180
13 Brookes MJ, Chan CD, Baljer B. et al. Surgical Advances in Osteosarcoma. Cancers (Basel) 2021; 13 (03) 388
14 Ferguson PC, McLaughlin CE, Griffin AM, Bell RS, Deheshi BM, Wunder JS. Clinical and functional outcomes of patients with a pathologic fracture in high-grade osteosarcoma. J Surg Oncol 2010; 102 (02) 120-124
15 He F, Zhang W, Shen Y. et al. Effects of resection margins on local recurrence of osteosarcoma in extremity and pelvis: Systematic review and meta-analysis. Int J Surg 2016; 36 ( Pt A ): 283-292
16 Lawrenz JM, Mesko NW. General Principles of Wide Resection of Bone Tumors. In Orthopaedic Knowledge Update Musculoskeletal Tumors 4. Rosemont: Illinois: American Academy of Orthopaedic Surgeons; Wolters Kluwer; 2021: 407-422
17 Loh AHP, Wu H, Bahrami A. et al. Influence of bony resection margins and surgicopathological factors on outcomes in limb-sparing surgery for extremity osteosarcoma. Pediatr Blood Cancer 2015; 62 (02) 246-251
18 Malawer MM, Wittig JC, Bickels J, Wiesel SW. Operative Techniques in Orthopaedic Surgical Oncology. 2nd ed. Philadelphia: Wolters Kluwer; 2016
19 Ayerza MA, Farfalli GL, Aponte-Tinao L, Muscolo DL. Does increased rate of limb-sparing surgery affect survival in osteosarcoma?. Clin Orthop Relat Res 2010; 468 (11) 2854-2859
20 Aponte-Tinao LA, Ayerza MA, Albergo JI, Farfalli GL. Do Massive Allograft Reconstructions for Tumors of the Femur and Tibia Survive 10 or More Years after Implantation?. Clin Orthop Relat Res 2020; 478 (03) 517-524
21 Hamed Kassem Abdelaal A, Yamamoto N, Hayashi K, Takeuchi A, Miwa S, Tsuchiya H. Epiphyseal Sparing and Reconstruction by Frozen Bone Autograft after Malignant Bone Tumor Resection in Children. Sarcoma 2015; 2015: 892141
22 Gross SW. The Classic: sarcoma of the long bones: based upon a study of one hundred and sixty-five cases. 1879. Clin Orthop Relat Res 2005; 438 (438) 9-14
23 Broström LA, Strander H, Nilsonne U. Survival in osteosarcoma in relation to tumor size and location. Clin Orthop Relat Res 1982; (167) 250-254
24 Taylor WF, Ivins JC, Dahlin DC, Edmonson JH, Pritchard DJ. Trends and variability in survival from osteosarcoma. Mayo Clin Proc 1978; 53 (11) 695-700
25 Eilber F, Giuliano A, Eckardt J, Patterson K, Moseley S, Goodnight J. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 1987; 5 (01) 21-26
26 Rosen G, Murphy ML, Huvos AG, Gutierrez M, Marcove RC. Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer 1976; 37 (01) 1-11
27 Bielack SS, Smeland S, Whelan JS. et al; EURAMOS-1 investigators. Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial. [published correction appears in J Clin Oncol 2016;34(33):4059] J Clin Oncol 2015; 33 (20) 2279-2287
28 Ward WG, Mikaelian K, Dorey F. et al. Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases. J Clin Oncol 1994; 12 (09) 1849-1858
29 Akazawa R, Umeda K, Saida S. et al. Temozolomide and etoposide combination for the treatment of relapsed osteosarcoma. Jpn J Clin Oncol 2020; 50 (08) 948-952
30 Senerchia AA, Macedo CR, Ferman S. et al. Results of a randomized, prospective clinical trial evaluating metronomic chemotherapy in nonmetastatic patients with high-grade, operable osteosarcomas of the extremities: A report from the Latin American Group of Osteosarcoma Treatment. Cancer 2017; 123 (06) 1003-1010
31 Sharma S, White D, Imondi AR, Placke ME, Vail DM, Kris MG. Development of inhalational agents for oncologic use. [published correction appears in J Clin Oncol 2001;19(9):2583] J Clin Oncol 2001; 19 (06) 1839-1847
32 Kiany S, Gordon N. Aerosol Delivery of Interleukin-2 in Combination with Adoptive Transfer of Natural Killer Cells for the Treatment of Lung Metastasis: Methodology and Effect. Methods Mol Biol 2016; 1441: 285-295
33 Gordon N, Felix K, Daw NC. Aerosolized Chemotherapy for Osteosarcoma. Adv Exp Med Biol 2020; 1257: 67-73
34 Chen Y, Liu R, Wang W. et al. Advances in targeted therapy for osteosarcoma based on molecular classification. Pharmacol Res 2021; 169: 105684
35 Chen C, Xie L, Ren T, Huang Y, Xu J, Guo W. Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs. Cancer Lett 2021; 500: 1-10
36 Dobrenkov K, Ostrovnaya I, Gu J, Cheung IY, Cheung NK. Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults. Pediatr Blood Cancer 2016; 63 (10) 1780-1785
37 Wang Y, Yu W, Zhu J. et al. Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma. J Exp Clin Cancer Res 2019; 38 (01) 168